A panel of federal advisers told the FDA that it should approve Kynapid but reject Pulzium to treat atrial fibrillation, a condition in which the two uppermost chambers of the heart beat irregularly and at an extremely rapid rate. (BioWorld Today)

A panel of federal advisers told the FDA that it should approve Kynapid but reject Pulzium to treat atrial fibrillation, a condition in which the two uppermost chambers of the heart beat irregularly and at an extremely rapid rate. (BioWorld Today)

Erythropoiesis-stimulating agents (ESAs), such as Aranesp, Epogen and Procrit, may increase the risk of acute leukemia in patients with a certain bone marrow disorder, researchers reported at the American Society of Hematology's annual meeting in Atlanta. (BioWorld Today)

Erythropoiesis-stimulating agents (ESAs), such as Aranesp, Epogen and Procrit, may increase the risk of acute leukemia in patients with a certain bone marrow disorder, researchers reported at the American Society of Hematology's annual meeting in Atlanta. (BioWorld Today)